Biotech | March 12, 2022
BioPharma’s Herceptin biosimilar Phase 3 results positive
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Subscribe To Our Newsletter & Stay Updated